Introduction {#Sec1}
============

In the USA, osteoporosis is an important health concern in the population of approximately 54 million people over the age of 50 \[[@CR1]\] and is characterized by reduced bone mineral density (BMD), deterioration in bone microstructure, and increased risk of fracture \[[@CR2]\]. Osteoporosis is the primary underlying cause of fractures in the elderly and contributes more than 2 million fractures each year \[[@CR3]\]. Fracture incidence increases with age for hip, vertebral, and most nonvertebral sites \[[@CR4]\]. Total incident hip fractures are expected to increase with the aging of the population, even though recent studies suggest that hip fracture incidences show secular declines in the USA \[[@CR5]\], Canada \[[@CR6]\], and Europe \[[@CR7], [@CR8]\] or may be leveling off \[[@CR9]\]. In the USA from 2015 to 2025, the total annual number of incident fractures is predicted to rise by 21% (from 2.51 to 3.04 million), and total hip fractures are projected to increase by 26% (from 335,000 to 447,000), assuming constant incidence, or to increase by 16%, assuming declining incidence \[[@CR3]\].

Hip fractures are associated with increased risk of further fractures, increased morbidity and mortality, and profound temporary or permanent impairment of independence and quality of life \[[@CR10]--[@CR14]\].

Teriparatide (parathyroid hormone \[1--34\] \[recombinant DNA origin\]) stimulates new bone formation on trabecular and cortical bone surfaces by preferential stimulation of osteoblastic activity over osteoclastic activity. In humans, the anabolic effects of teriparatide are manifest as an increase in skeletal mass, an increase in markers of bone formation and resorption, and an increase in bone strength \[[@CR15]--[@CR17]\]. Teriparatide is approved for treating postmenopausal women with osteoporosis at high risk for fracture, for increasing bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, and for treating men and women with glucocorticoid-induced osteoporosis at high risk for fracture \[[@CR18], [@CR19]\]. Teriparatide has been shown to reduce the risk of vertebral and nonvertebral fractures in randomized clinical trials \[[@CR15], [@CR20]\], in real-world observational studies \[[@CR21], [@CR22]\], and in retrospective claims database studies \[[@CR23]\]. However, real-world evidence is lacking on the effectiveness of teriparatide in reducing risk of hip fractures.

Proper adherence to medications is essential for achieving good outcomes \[[@CR24]\]. Similar to adherence for other chronic therapies, adherence to osteoporosis treatments is suboptimal: more than half of patients failed to comply or persist with their medication regimens at 1 year \[[@CR24]--[@CR29]\]. Teriparatide therapy persistence at 12 months has been reported to range from 57 to 77% \[[@CR21], [@CR23], [@CR30], [@CR31]\].

Previous research on teriparatide adherence and persistence supports the hypothesis that longer duration and higher rates of adherence are associated with improved patient outcomes \[[@CR20]--[@CR23], [@CR32]--[@CR35]\]. Moreover, retrospective claims database studies have reported lower nonvertebral fracture incidence with longer exposures \[[@CR23], [@CR33], [@CR34]\]. In the 2012 claims database study by Yu and colleagues, all-clinical, clinical vertebral, and nonvertebral fracture incidence were statistically significantly lower for more persistent and adherent patients than for those patients with the least persistence and worst adherence \[[@CR23]\]. Because most studies of teriparatide have a relatively small number of fractures, additional information from a larger group of patients treated with teriparatide might be helpful to clarify the effects of teriparatide on fractures. Furthermore, previous studies have only examined the association between teriparatide exposure and fracture incidence and have not adequately evaluated the real-world effectiveness or possible causality of teriparatide in terms of reducing the risk of incident fractures. Therefore, our study extends Yu and colleagues' 2012 claims database study by using 11 years of on-market and more recent data to examine both the association and the real-world effectiveness of teriparatide treatment on the incidence of hip and other fractures in the United States.

Materials and methods {#Sec2}
=====================

Data source {#Sec3}
-----------

This study was conducted by using the Truven MarketScan Research Databases from 01 January 2004 to 31 December 2014.

Study population {#Sec4}
----------------

The study population consisted of new teriparatide (parathyroid hormone \[1--34\] \[recombinant DNA origin\]) users aged 18 years and older. New users were defined as having no pharmacy claims for teriparatide during the 12 months before the first prescription dispensed and at least 1 prescription filled for teriparatide. The date the first prescription was dispensed was defined as the index date, with the index teriparatide prescription occurring between 1 January 2005 and 31 December 2012. New users were required to have continuous medical and pharmacy coverage 12 months before and 24 months after the first teriparatide prescription was dispensed. Patients diagnosed with Paget disease were identified by International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) code 731.0 and/or specific medication dosing (alendronate sodium 40 mg daily and risedronate sodium 30 mg daily) and were excluded from the study population.

Baseline patient characteristics, including age and gender, were recorded as of the date of the first teriparatide prescription. Clinical characteristics included assessments of health status, measured by the Deyo Charlson Comorbidity Index (CCI), whether a BMD test had been performed, and the number of fractures reported during the 12 months before the first teriparatide prescription. Confounding medications included osteoporosis medications (bisphosphonates, selective estrogen receptor modulator \[SERM\], calcitonin, denosumab, and hormone therapy) and medications known to be associated with bone loss or risk of fracture (glucocorticoids, hormone deprivation therapy, anticonvulsants, and immunosuppressants) \[[@CR26], [@CR36], [@CR37]\]. All baseline characteristics were used as covariates in the multivariate regression models. All covariates were categorical variables except age and Deyo CCI score, which were continuous variables.

Adherence and persistence {#Sec5}
-------------------------

Medication adherence was measured by the medication possession ratio (MPR), defined as the sum of days of supply dispensed divided by the total number of days of the post-index period. An MPR greater than or equal to 0.80 was defined as high, 0.50 ≤ MPR \< 0.80 was defined as medium, and \<0.50 was defined as low adherence for osteoporosis medication \[[@CR23]--[@CR25]\].

Medication persistence was measured as teriparatide use with gaps in treatment of less than or equal to 90 days, where the gap was measured from last date of therapy (date of last day of drug supply) to the beginning date of the subsequent therapy prescription. All patients without gaps in teriparatide of more than 90 days were considered "persistent." Medication persistence was calculated as a categorical variable, and patients were entered into 1 of 4 persistence groups: 1--6, 7--12, 13--18, and 19--24 months. Medication persistence categorical variables were used in the descriptive and multivariate regression analyses.

Fractures {#Sec6}
---------

New incident fractures were identified by a claims-based algorithm at the 3-digit level of an ICD-9-CM code (see Online Resource [1](#MOESM1){ref-type="media"}). Fracture sites were categorized as any, vertebral, nonvertebral, hip, and wrist. Pathological fractures were included on the basis of the recommendation by Curtis and colleagues from epidemiologic studies of osteoporotic fractures \[[@CR38]\]. Fractures that occurred after 90 days from the index date were considered incident fractures to provide sufficient time for therapeutic effects from teriparatide to begin. The 90-day interval for onset of teriparatide effect is supported by work from Bonafede et al. using the same claims database \[[@CR34]\]; during the year prior to teriparatide, 25.6% of the patients had fragility fracture claims and this approximate rate of fracture continued during the initial 90 days of teriparatide, but was lower thereafter \[[@CR34], [@CR35]\]. Hip fractures were identified by fracture diagnoses from inpatient admission claims. Vertebral fractures were identified by spine imaging tests within 30 days of fracture diagnoses. Nonvertebral and other fractures were identified from the primary ICD-9-CM codes on inpatient or outpatient admission claims. Subsequent fracture diagnoses could be claimed if the new claim was \>180 days from the original fracture.

Statistical methods {#Sec7}
-------------------

SAS version 9.2 (SAS Institute Inc., Cary, NC, USA) was used for analytic file construction and all statistical analyses. Descriptive statistics for baseline and clinical characteristics, medication use, and previous fracture history were reported for the total study population and by MPR and persistence groups. Mean and standard deviation were reported for continuous variables, and number and percentage were reported for categorical variables. Means were tested using analysis of variance (ANOVA); percentages were tested using chi-square tests.

Unadjusted fracture incidence per 1000 patient years (PYs) were reported by fracture type and compared using ANOVA. The association between teriparatide exposure, based on persistence and adherence categories, and incident fractures was evaluated by using logistic regression analyses performed by fracture type (any, vertebral, nonvertebral, hip, and wrist) for modeling the probability of fractures over 24 months, adjusted for MPR and persistence in a time-invariant manner, and baseline covariates. Odds ratios (OR), 95% confidence intervals, and associated *P* values were reported for all the variables included in the logistic regressions, as were the type III analyses of effects for categorical variables with more than two categories.

Real-world effectiveness of adherence to teriparatide therapy on particular fracture site risk, by fracture type (any, vertebral, nonvertebral, hip, and wrist), was analyzed with Cox proportional hazard models using time-dependent cumulative adherence of teriparatide (censored at time of first outcome fracture or 24 months), adjusting for occurrence of other fractures (yes/no) preceding the main fracture outcome and adjusting for all baseline covariates used in logistic regression models above. The dependent variable in each model was time to the first incident fracture, and patients' adherence levels (low, moderate, or high) were calculated from the index date in cumulative 30-day intervals. When a fracture occurred, the cumulative MPR for the period preceding the fracture was applied.

In real-world settings, a source of possible confounding is the "healthy adherer" effect or "adherence bias," whereby patients who are more adherent to medications may differ in important health-seeking behaviors and other aspects that affect outcomes from those who are not adherent to their medications. This phenomenon may lead to biased estimates of treatment effects when health status and healthy behaviors are not measured and adjusted for in the analyses. Claims databases (including the Truven MarketScan Research Databases used in this study) have limited or insufficient measures of health status and healthly lifestyle behaviors. Therefore, we conducted diagnostic tests for potential healthy adherer bias using control outcomes hypothesized to be unrelated to osteoporosis or teriparatide's treatment effects \[[@CR39], [@CR40]\]. As proxy measures, differences in these outcomes between adherence groups would reflect underlying, unmeasured differerences in health status and/or healthy behaviors. The control outcomes or "falsification" endpoints used to test for differences by teriparatide persistence and adherence groups included the six most frequent hospital admissions (expected to be unrelated to osteoporosis or teriparatide's effects) during the post-index period (i.e., those with primary ICD-9-CM diagnoses of 486 \[pneumonia, organism unspecified\]; 491.21 \[obstructive chronic bronchitis, with \[acute\] exacerbation\]; 599.0 \[urinary tract infection, site not specified\]; 427.31 \[atrial fibrillation\]; 414.01 \[coronary atherosclerosis of native coronary artery\]; or 038.9 \[unspecified septicemia\]) (see Online Resource [2](#MOESM2){ref-type="media"}, [3](#MOESM3){ref-type="media"}, [4](#MOESM4){ref-type="media"}).

Results {#Sec8}
=======

There were 14,284 new teriparatide users aged 18 years or older reported in this study (Fig. [1](#Fig1){ref-type="fig"}). The numbers of patients in the low-, medium-, and high-MPR groups were 5469 (38.3%), 2442 (17.1%), and 6373 (44.6%), respectively (Table [1](#Tab1){ref-type="table"}). The numbers of patients in the 1--6, 7--12, 13--18, and 19--24 months persistence groups were 3916 (27.4%), 1968 (13.8%), 1842 (12.9%), and 6558 (45.9%), respectively (Table [2](#Tab2){ref-type="table"}). Baseline characteristics included mean age 68.35 years, 89.8% female, and 29.6% had a previous fracture (Table [1](#Tab1){ref-type="table"}). The baseline Deyo CCI score was significantly different across MPR groups, with scores higher (representing worse health scores) in the low-MPR group (1.09) than in the high-MPR group (0.90). The frequency of patients who had a BMD test prior to beginning teriparatide was significantly greater in the high-MPR group (85.0%) than in the low-MPR group (77.7%). Baseline glucocorticoid and anticonvulsant use was significantly more common in the low-MPR group (44.2 and 18.8%, respectively) than in the high-MPR group (37.9 and 15.1%), and baseline bisphosphonate and SERM use was more common in the high-MPR group (59.3 and 11.0%, respectively) than in the low-MPR group (43.2 and 8.4%, respectively) (all *P* \< .001; Table [1](#Tab1){ref-type="table"}). Similar baseline results were observed across persistence groups; Deyo CCI scores were highest in the 1--6-month persistence group (1.15), BMD test frequency was highest in the 19--24-month persistence group (85.0%), glucocorticoid and anticonvulsant use was most common in the 1--6-month persistence group (45.3 and 19.5%, respectively), and bisphosphonate and SERM use was most common in the 19--24-month persistence group (58.9 and 11.0%, respectively) (all *P* \< .001; Table [2](#Tab2){ref-type="table"}).Fig. 1Patient selection Table 1Baseline characteristics by MPR groupMPRTotal (*N* = 14,284)Low (*N* = 5469)Medium (*N* = 2442)High (*N* = 6373)*P* valueAge, yearsAge, mean (SD)68.35 (12.01)68.06 (12.91)67.56 (12.00)68.90 (11.15)\<.001Age group, *N* (%)\<.001 18--44284 (2.0)171 (3.1)52 (2.1)61 (1.0) 45--541445 (10.1)650 (11.9)263 (10.8)532 (8.3) 55--644220 (29.5)1506 (27.5)794 (32.5)1920 (30.1) 65--743299 (23.1)1146 (21.0)550 (22.5)1603 (25.2) 75--843845 (26.9)1473 (26.9)590 (24.2)1782 (28.0)  ≥ 851191 (8.3)523 (9.6)193 (7.9)475 (7.5)Sex, *N* (%)Female12,822 (89.8)4904 (89.7)2207 (90.4)5711 (89.6).55Male1462 (10.2)565 (10.3)235 (9.6)662 (10.4)Clinical characteristicsBMD test (yes/no), *N* (%)11,722 (82.1)4249 (77.7)2058 (84.3)5415 (85.0)\<.001Previous fracture (yes/no), *N* (%)4235 (29.6)1593 (29.1)767 (31.4)1875 (29.4).11Deyo CCI, mean (SD)0.99 (1.42)1.09 (1.49)1.02 (1.44)0.90 (1.35)\<.001Confounding medication, *N* (%)Glucocorticoids5872 (41.1)2417 (44.2)1040 (42.6)2415 (37.9)\<.001Hormone deprivation154 (1.1)58 (1.1)27 (1.1)69 (1.1).98Anticonvulsants2450 (17.2)1029 (18.8)458 (18.8)963 (15.1)\<.001Immunosuppressants1367 (9.6)526 (9.6)260 (10.6)581 (9.1).09Other OP medication, *N* (%)Bisphosphonates7392 (51.8)2360 (43.2)1255 (51.4)3777 (59.3)\<.001SERM use1393 (9.8)457 (8.4)238 (9.7)698 (11.0)\<.001Calcitonin9 (0.1)4 (0.1)3 (0.1)2 (0.0).29Denosumab5 (0.0)2 (0.0)1 (0.0)2 (0.0).97Hormone therapy1794 (12.6)687 (12.6)317 (13.0)790 (12.4).75*P* values for frequencies obtained from chi-square tests; *P* values for mean age and mean Deyo CCI scores obtained from ANOVA *F* test*ANOVA* analysis of variance, *BMD* bone mineral density, *CCI* Charlson comorbidity index, *MPR* medication possession ratio, *OP* osteoporosis, *SD* standard deviation, *SERM* selective estrogen receptor modulator Table 2Baseline characteristics by persistence groupPersistenceTotal (*N* = 14,284)1--6 months (*N* = 3916)7--12 months (*N* = 1968)13--18 months (*N* = 1842)19--24 months (*N* = 6558)*P* valueAge, yearsAge, mean (SD)68.35 (12.01)67.46 (13.08)67.08 (12.28)67.67 (11.94)68.86 (11.21)\<.001Age group, *N* (%)\<.001 18--44284 (2.0)133 (3.4)44 (2.2)39 (2.1)68 (1.0) 45--541445 (10.1)440 (11.2)267 (13.6)189 (10.3)549 (8.4) 55--644220 (29.5)1029 (26.3)606 (30.8)599 (32.5)1986 (30.3) 65--743299 (23.1)821 (21.0)424 (21.5)414 (22.5)1640 (25.0) 75--843845 (26.9)1084 (27.7)485 (24.6)457 (24.8)1819 (27.7)  ≥ 851191 (8.3)409 (10.4)142 (7.2)144 (7.8)496 (7.6)Sex, *N* (%)Female12,822 (89.8)3501 (89.4)1780 (90.4)1662 (90.2)5879 (89.6).55Male1462 (10.2)415 (10.6)188 (9.6)180 (9.8)679 (10.4)Clinical characteristicsBMD test (yes/no), *N* (%)11,722 (82.1)3003 (76.7)1586 (80.6)1559 (84.6)5574 (85.0)\<.001Previous fracture (yes/no), *N* (%)4235 (29.6)1162 (29.7)562 (28.6)575 (31.2)1936 (29.5).34Deyo CCI, mean (SD)0.99 (1.42)1.15 (1.50)0.99 (1.47)1.00 (1.41)0.90 (1.35)\<.001Confounding medication, *N* (%)Glucocorticoids5872 (41.1)1773 (45.3)841 (42.7)745 (40.4)2513 (38.3)\<.001Hormone deprivation154 (1.1)45 (1.1)17 (0.9)22 (1.2)70 (1.1).74Anticonvulsants2450 (17.2)763 (19.5)362 (18.4)337 (18.3)988 (15.1)\<.001Immunosuppressants1367 (9.6)388 (9.9)202 (10.3)179 (9.7)598 (9.1).36Other OP medication, *N* (%)Bisphosphonates7392 (51.8)1668 (42.6)901 (45.8)958 (52.0)3865 (58.9)\<.001SERM1393 (9.8)312 (8.0)188 (9.6)173 (9.4)720 (11.0)\<.001Calcitonin9 (0.1)3 (0.1)1 (0.1)2 (0.1)3 (0.0).78Denosumab5 (0.0)2 (0.1)01 (0.1)2 (0.0).75Hormone therapy1794 (12.6)488 (12.5)263 (13.4)241 (13.1)802 (12.2).51*P* values for frequencies obtained from chi-square tests; *P* values for mean age and mean Deyo CCI scores obtained from ANOVA *F* test*ANOVA* analysis of variance, *BMD* bone mineral density, *CCI* Charlson Comorbidity Index, *OP* osteoporosis, *SD* standard deviation, *SERM* selective estrogen receptor modulator

The mean (SD) exposure to teriparatide was 431.7 (260.2) days. The unadjusted incidence per 1000 PYs by MPR group for any clinical fracture ranged from 82.9 (low MPR) to 55.6 (high MPR). Fracture incidence per 1000 PYs by MPR group is displayed graphically in Fig. [2](#Fig2){ref-type="fig"}a. The unadjusted incidence per 1000 PYs by persistence group for any clinical fracture ranged from 91.2 (1--6 months) to 55.5 (19--24 months). Fracture incidence per 1000 PYs by persistence group is displayed graphically in Fig. [2](#Fig2){ref-type="fig"}b. The proportion of patients with one fracture or with multiple fractures generally decreased as MPR or persistence increased for all fracture types except wrist fracture (see Online Resource [5](#MOESM5){ref-type="media"}).Fig. 2Fracture incidence per 1000 patient years

The results from the logistic regression models indicate that the effects of adherence and persistence were statistically significant (*P* \< .001) for all fracture types except wrist fracture (*P* ≥ .125) (Table [3](#Tab3){ref-type="table"}). Furthermore, high adherence (MPR) was associated with significantly lower risk than low adherence for any fracture (O = 0.67; *P* \< .001), vertebral fracture (OR = 0.64; *P* \< .001), nonvertebral fracture (OR = 0.71; *P* \< .001), and hip fracture (OR = 0.52; *P* \< .001). High and medium adherence compared to low adherence was not associated with reduced risk for wrist fracture (Table [3](#Tab3){ref-type="table"}). Patients with longer persistence (19--24 months) were significantly less likely than patients with shorter persistence (1--6 months) to have any fracture (OR = 0.63, *P* \< .001), vertebral fracture (OR = 0.56, *P* \< .001), nonvertebral fracture (OR = 0.69, *P* \< .001), and hip fracture (OR = 0.48, *P* \< .001, Table [3](#Tab3){ref-type="table"}).Table 3Logistic regression: comparison of fracture incidence (yes/no) among different teriparatide adherence and persistence groups, adjusted for baseline confoundersAny fractureVertebral fractureNonvertebral fractureHip fractureWrist fractureOR \[95% CI\]*P* value^a^OR \[95% CI\]*P* value^a^OR \[95% CI\]*P* value^a^OR \[95% CI\]*P* value^a^OR \[95% CI\]*P* value^a^Adherence\<.001^b^\<.001^b^\<.001\<.001^b^.125^b^Medium vs low0.92 \[0.79, 1.06\].240.86 \[0.70, 1.06\].160.95 \[0.79, 1.14\].590.77 \[0.54, 1.10\].151.13 \[0.84, 1.51\].411High vs low0.67 \[0.60, 0.76\]\<.0010.64 \[0.54, 0.76\]\<.0010.71 \[0.61, 0.82\]\<.0010.52 \[0.39, 0.70\]\<.0010.85 \[0.66, 1.08\].175Persistence\<.001^b^\<.001^b^\<.001^b^\<.001^b^.3227--12 vs 1--6 months0.87 \[0.74, 1.03\].110.73 \[0.58, 0.94\].0110.95 \[0.78, 1.16\].610.78 \[0.53, 1.14\].190.93 \[0.66, 1.31\].68813--18 vs 1--6 months0.78 \[0.65, 0.92\].0040.72 \[0.56, 0.92\].0090.83 \[0.67, 1.03\].090.64 \[0.42, 0.98\].040.95 \[0.67, 1.34\].75519--24 vs 1--6 months0.63 \[0.55, 0.71\]\<.0010.56 \[0.47, 0.67\]\<.0010.69 \[0.59, 0.81\]\<.0010.48 \[0.36, 0.66\]\<.0010.79 \[0.61, 1.03\].076Age1.02 \[1.01, 1.02\]\<.0011.02 \[1.02, 1.03\]\<.0011.01 \[1.01, 1.02\]\<.0011.04 \[1.03, 1.06\]\<.0011.00 \[0.99, 1.01\].963SexFemale vs male1.13 \[0.95, 1.35\].180.83 \[0.66, 1.04\].111.52 \[1.20, 1.92\]\<.0011.60 \[1.00, 2.57\].051.77 \[1.16, 2.72\].009Region.31^b^.36^b^.27^b^.26^b^.856^b^North Central vs South1.05 \[0.92, 1.19\].460.90 \[0.75, 1.08\].261.16 \[0.99, 1.35\].071.29 \[0.96, 1.73\].101.05 \[0.81, 1.35\].725Northeast vs South1.20 \[0.99, 1.47\].071.16 \[0.88, 1.53\].281.24 \[0.98, 1.58\].071.03 \[0.63, 1.70\].901.26 \[0.86, 1.84\].258Unknown vs South0.39 \[0.05, 2.99\].37\<0.001 \[\<0.001, ∞\].970.70 \[0.09, 5.28\].723.63 \[0.46, 28.75\].22\<0.001 \[\<0.001, ∞\].973West vs South0.99 \[0.84, 1.16\].890.88 \[0.70, 1.11\].281.07 \[0.88, 1.30\].490.93 \[0.63, 1.39\].731.08 \[0.79, 1.48\].645Plan type.18^b^.09^b^.07^b^.16^b^.523^b^HDHP vs comprehensive2.29 \[0.93, 5.66\].070.85 \[0.11, 6.48\].882.82 \[1.07, 7.39\].047.97 \[1.80, 35.30\].012.24 \[0.52, 9.57\].278HMO vs comprehensive1.08 \[0.85, 1.38\].511.35 \[0.97, 1.88\].070.87 \[0.64, 1.18\].361.00 \[0.54, 1.87\]1.000.74 \[0.44, 1.25\].260Other vs comprehensive1.08 \[0.86, 1.35\].520.80 \[0.55, 1.16\].231.31 \[1.01, 1.70\].041.27 \[0.73, 2.21\].391.14 \[0.75, 1.74\].540PPO vs comprehensive1.15 \[1.02, 1.31\].031.19 \[1.00, 1.42\].051.08 \[0.93, 1.26\].321.09 \[0.82, 1.46\].561.06 \[0.83, 1.37\].646Unknown vs comprehensive1.11 \[1.07, 1.15\].641.20 \[0.65, 2.21\].561.14 \[0.66, 1.97\].641.18 \[0.42, 3.29\].750.64 \[0.20, 2.05\].448Deyo Charlson Comorbidity Index1.11 \[1.07, 1.15\]\<.0011.07 \[1.02, 1.12\].0031.11 \[1.07, 1.16\]\<.0011.08 \[1.00, 1.17\].061.09 \[1.02, 1.17\].011BMD test: yes vs no0.94 \[0.84, 1.05\].280.95 \[0.81, 1.12\].530.89 \[0.77, 1.02\].100.80 \[0.61, 1.04\].101.01 \[0.80, 1.28\].908Preindex fracture: yes vs no2.92 \[2.61, 3.26\]\<.0013.78 \[3.21, 4.45\]\<.0012.19 \[1.91, 2.52\]\<.0012.24 \[1.71, 2.94\]\<.0011.55 \[1.23, 1.95\]\<.001Medication use: yes vs noGlucocorticoids1.23 \[1.10, 1.37\]\<.0011.35 \[1.15, 1.59\]\<.0011.16 \[1.01, 1.33\].031.01 \[0.77, 1.32\].941.20 \[0.96, 1.50\].116Hormone deprivation0.65 \[0.37, 1.15\].140.57 \[0.23, 1.42\].230.75 \[0.39, 1.45\].400.98 \[0.31, 3.18\].980.65 \[0.21, 2.08\].471Anticonvulsants1.57 \[1.39, 1.79\]\<.0011.72 \[1.45, 2.05\]\<.0011.42 \[1.21, 1.66\]\<.0011.67 \[1.24, 2.24\]\<.0011.06 \[0.80, 1.39\].703Immunosuppressants1.04 \[0.88, 1.24\].641.20 \[0.95, 1.52\].120.93 \[0.75, 1.15\].491.36 \[0.92, 2.01\].120.72 \[0.49, 1.07\].105Bisphosphonates1.12 \[1.01, 1.25\].041.14 \[0.98, 1.34\].091.12 \[0.98, 1.28\].100.94 \[0.73, 1.22\].651.24 \[1.00, 1.55\].045SERM0.89 \[0.73, 1.08\].230.97 \[0.73, 1.29\].830.83 \[0.65, 1.06\].130.76 \[0.47, 1.25\].280.76 \[0.51, 1.15\].200Calcitonin\<0.001 \[\<0.001, ∞\].96\<0.001 \[\<0.001, ∞\].98\<0.001 \[\<0.001, ∞\].96\<0.001 \[\<0.001, ∞\].98\<0.001 \[\<0.001, ∞\].983Hormone therapy0.95 \[0.79, 1.13\].550.96 \[0.73, 1.25\].760.95 \[0.77, 1.18\].660.68 \[0.40, 1.15\].150.97, \[0.70, 1.36\].870*BMD* bone mineral density, *HDHP* high-deductible health plan, *HMO* health maintenance organization, *OR* odds ratio, *PPO* preferred-provider organizations, *SERM* selective estrogen receptor modulator^a^ *P* values are pairwise comparisons unless otherwise noted^b^ *P* value is an overall comparison

In Cox proportional hazard modeling (Table [4](#Tab4){ref-type="table"}), the effect of adherence to teriparatide was statistically significant (*P* ≤ .002) for all fracture types except wrist fracture (*P* = .55). In addition, significantly lower risk was seen for any fracture (OR = 0.79, *P* = .001) and vertebral fracture (OR = 0.68, *P* \< .001) for medium adherence than for low adherence and for any fracture (OR = 0.69, *P* \< .001), vertebral fracture (OR = 0.60, *P* \< .001), nonvertebral fracture (OR = 0.77, *P* \< .001), and hip fracture (OR = 0.55, *P* \< .001) for high adherence than for low adherence (see Online Resource [6](#MOESM6){ref-type="media"} for a complete presentation of all factors in the model; these results were similar to those seen with the logistic regression).Table 4Cox regression: comparison of fracture incidence (yes/no) among different teriparatide cumulative adherence groups, adjusted for baseline confounders and time-dependent post-index other fracturesAny fractureVertebral fractureNonvertebral fractureHip fractureWrist fractureOR \[95% CI\]*P* value^a^OR \[95% CI\]*P* value^a^OR \[95% CI\]*P* value^a^OR \[95% CI\]*P* value^a^OR \[95% CI\]*P* value^a^Adherence\<.001^b^\<.001^b^.002^b^\<.001^b^.55^b^Medium vs low0.79 \[0.68, 0.91\].0010.68 \[0.55, 0.84\]\<.0010.87 \[0.73, 1.05\].150.74 \[0.51, 1.05\].090.89 \[0.65, 1.23\].49High vs low0.69 \[0.62, 0.77\]\<.0010.60 \[0.51, 0.71\]\<.0010.77 \[0.66, 0.89\]\<.0010.55 \[0.42, 0.74\]\<.0010.87 \[0.68, 1.12\].28*OR* odds ratio^a^ *P* values are pairwise comparisons unless otherwise noted^b^ *P* value is an overall comparison

After stopping teriparatide (a treatment gap of at least 90 days), use of osteoporosis medications other than teriparatide was 45.1% (31.8% bisphosphonate) in the 1 to 6-month group, 36.9% (23.8% bisphosphonate) in the 7 to 12-month group, 32.6% (20.5% bisphosphonate) in the 13 to 18-month group, and 14.6% (8.1% bisphosphonate) in the 19--24-month group. The control outcomes analyses revealed inconsistent evidence regarding potential healthy adherer bias. In two of the six hospital admission types, there were statistically significant differences in the incidence per 1000 PYs across the adherence and persistence groups (urinary tract infection), while coronary athlerosclerosis of native coronary artery had a statistically significant difference across persistence groups but not for adherence groups. However, even where statistically significant differences were found, the incidence patterns generally were not consistent across the exposure groups, as increases and decreases in incidence were observed with longer persistence. There were no statistically significant differences estimated in any of the analyses for pneumonia--organism unspecified, obstructive chronic bronchitis with acute exacerbation, atrial fibrillation, or unspecified septicemia (see Online Resource [2](#MOESM2){ref-type="media"}, [3](#MOESM3){ref-type="media"}, [4](#MOESM4){ref-type="media"}).

Discussion {#Sec9}
==========

Evidence of therapy benefits under real-world clinical conditions, or real-world evidence, is becoming increasingly important to payers and health care providers as the need to allocate scarce budgets more efficiently and to improve patient outcomes intensifies. The current study uses a real-world US claims database to examine the relationship between teriparatide adherence and persistence and hip and other fracture incidences. The results show fracture incidence decreased as adherence or persistence increased for any, vertebral, nonvertebral, and hip fractures.

Hip fracture is an important clinical end point for osteoporosis medications. In many smaller studies, the hip fracture end point has not been examined because of insufficient numbers of events. A recent review of teriparatide use reported increases in cancellous bone volume, improvement in bone architecture, and increases in cortical thickness associated with increased cortical remodeling \[[@CR41]\]. Additionally, teriparatide 20 μg/day increased femoral neck and total hip BMD; the gains continued during ongoing treatment through 24 months \[[@CR41]\]. The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study evaluated over 4000 men and women receiving teriparatide for 24 months who were then followed up for an additional 24 months after treatment \[[@CR41], [@CR22]\]. The incidence of patients experiencing a new nonvertebral fragility fracture was 1.42, 0.91, 0.70, and 0.81% for the 0--6-, 6--12-, 12--18-, and 18--24-month treatment periods, and this trend persisted after teriparatide treatment was discontinued \[[@CR22], [@CR41]\]. Hip fractures as a percentage of patients at risk decreased as treatment duration increased 0.27% (10/3720 patients), 0.067% (2/3010 patients), 0.15% (4/2629 patients), and 0% (0/2287 patients) for the 0--6-, 6--12-, 12--18-, and 18--24-month treatment periods \[[@CR41]\].

In Yu and colleagues' study, hip fracture incidence appeared to decrease with longer exposure, though in multivariate models the association of teriparatide exposure and incidence did not reach statistical significance (persistence 1--6 vs 19--24 months: OR = 1.93; *P* = .08). Our study extends the work of Yu and colleagues by using a larger and more recent database and by applying Cox proportional hazard models with time-dependent covariates for cumulative teriparatide exposure to show the effect of adherence to therapy on fracture incidence. Our study is the first to demonstrate real-world effectiveness of teriparatide in reducing the risk of hip and other fragility fractures in the USA.

The wrist has proven to be a difficult site for which to demonstrate reduced fracture risk in studies of osteoporosis because high forces are applied to the wrist as people brace themselves with their hands when falling, so it is common for people with healthy bones to experience wrist fractures. Clinical trials of osteoporosis drugs have shown inconsistent effects on wrist fractures or not reported this outcome \[[@CR42]\]. Our study reveals an inconsistent reduction in wrist fractures by MPR and persistence categories using logistic and Cox regressions; statistical significance was not achieved. The fact that increased teriparatide adherence and persistence did not significantly reduce wrist fracture risk might relate to teriparatide increasing cortical remodeling \[[@CR41]\] and decreasing bone mineral density at the radius \[[@CR15]\], although teriparatide increases cortical thickness \[[@CR41]\]. Alternatively, the lack of significance might be due to an insufficient number of wrist fractures; future analyses with larger numbers of events may clarify the effect of teriparatide at this site.

The study's limitations include those typical when claims databases are used, including lack of randomization, potential miscoding of the fracture type or overestimating or underestimating the fracture incidences; use of algorithms whose validity and reliability have not been established to identify incident fractures; lack of information on clinical risk factors (e.g., limited medical history, no family medical history, lifestyle risk factors, no BMD T scores); and the inability to ascertain actual patient adherence (e.g., proper injections) to therapy. In observational studies examining osteoporosis therapy adherence and healthy adherer bias, only limited evidence was found \[[@CR39], [@CR43]\]. In one study on Medicare patients, the association between high adherence with different medications (oral bisphosphonates, selective serotonine re-uptake inhibitors, angiotensin converting enzyme inhibitors, and calcium channel blockers) and fracture was examined to test for possible healthy adherer bias; and the authors concluded that the healthy adherer effect was limited \[[@CR39]\]. Another study examined the potential for healthy adherer bias in elderly Medicaid patients in Pennsylvania by estimating the association between adherence to osteoporosis therapies (raloxifene, calcitonin, oral bisphosphonates) and subsequent vaccination and health care testing \[[@CR43]\]. The authors reported there was limited evidence of a healthy adherer effect, although higher adherence with raloxifene was associated with higher fracture risk and was probably due to residual confounding in those patients \[[@CR44]\]. In our study, we examined six separate control outcomes and found mixed results and thus did not detect any strong evidence of healthy adherer bias. Nevertheless, we cannot conclusively claim absence of healthy adherer effects or bias within our estimates, though any such impacts would appear to be minimal. The use of osteoporosis medications known to reduce fracture risk after stopping teriparatide may represent a bias against showing teriparatide effectiveness in this analysis. Additionally, claims for incident fractures, especially with respect to incident compression vertebral fractures may be incorrect, and misclassification of outcomes may also represent a bias reducing the association of adherence with fracture risk reduction \[[@CR44]\].

In summary, teriparatide stimulates bone formation at the femur by histology, bone scan, and PET scan and has proven to increase femoral neck and total hip BMD \[[@CR41], [@CR45]\]. Clinical, observational, and claims database studies show fewer nonvertebral fractures (a composite end point including hip fractures) with longer teriparatide treatment than with shorter teriparatide treatment. The DANCE study and Yu and colleagues' claims database study show apparent decreases in numbers of hip fractures with longer than with shorter teriparatide treatment, although statistical significance was not reached in the Yu and colleagues study. Our study, with a larger sample of teriparatide-treated patients, confirms a statistically significant reduction in hip and other fragility fractures with longer persistence or higher adherence.

Conclusion {#Sec10}
==========

This study is the first to demonstrate real-world effectiveness of teriparatide to reduce the risk of hip fractures along with other fragility fractures in the USA. Among teriparatide patients in a US claims database who were observed for 2 years after teriparatide initiation, fracture incidence significantly decreased as adherence and persistence increased for vertebral, nonvertebral, hip, and any clinical fractures.
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